Corporate ActionAug 12, 2026, 05:32 PM
BioStem Uplists to Nasdaq; Q2 Revenue $7.9M, Raises FY26 Guidance
AI Summary
BioStem Technologies, Inc. announced its second quarter 2026 financial results, reporting net revenue of $7.9 million, a 29% sequential increase. The company also completed its uplisting to the Nasdaq Capital Market and secured a $2.5 million private placement. Despite the revenue growth and strategic milestones, BioStem reported a GAAP net loss of ($9.0) million and an Adjusted EBITDA loss of ($4.6) million for the quarter. Following these developments, the company raised its full-year 2026 revenue guidance to a range of $26 million to $29 million.
Key Highlights
- Uplisted common stock to the Nasdaq Capital Market on August 7, 2026.
- Completed a $2.5 million private placement with its first institutional investor.
- Generated Q2 2026 net revenue of $7.9 million, a 29% sequential increase.
- Reported Q2 2026 GAAP net loss of ($9.0) million, or ($0.52) per share.
- Adjusted EBITDA loss for Q2 2026 was ($4.6) million.
- Raised full-year 2026 revenue guidance to $26 million to $29 million.
- Issued eight new U.S. design patents for fenestrated human placental allograft technology.
- Cash and cash equivalents totaled $7.0 million as of June 30, 2026.
Price Impact
More from BSEM